Shots:
- ModeX & Regeneron entered into a license & collaboration agreement to develop multispecific antibodies across cancer and metabolic, combining ModeX’s MSTAR platform with Regeneron’s antibody binders
- Regeneron will fund & lead all development & commercialization in exchange for $7M upfront, plus future product selection, clinical, regulatory, & commercial milestones over $200M per molecule, with total deal value over $1B, if multiple products succeed, as well as tiered royalties up to low double digits at the highest tier
- MSTAR platform creates multispecific antibodies using modular building blocks to enhance potency, precision, & simultaneous targeting of multiple disease pathways
Ref: ModeX Therapeutics | Image: ModeX Therapeutics and Regeneron | Press Release
Related News:- Samsung Bioepis Enters Asset Purchase Deal with Biogen for Byooviz (Biosimilar, Lucentis) and Opuviz (Biosimilar, Eylea) in the EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
